



Cure VCP Disease, Inc.

**Financial Statements
For the Years Ended December 31, 2023 and 2022**

Cure VCP Disease, Inc.
Statements of Financial Position
December 31, 2023 and 2022

<u>Assets</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Current Assets		
Cash and Cash Equivalents	\$ 475,504	\$ 402,586
Accounts Receivable	9,463	4,225
Prepaid Expenses	4,000	-
Total Current Assets	<u>488,967</u>	<u>406,811</u>
Total Assets	<u><u>\$ 488,967</u></u>	<u><u>\$ 406,811</u></u>
 <u>Liabilities and Net Assets</u>		
Current Liabilities		
Accounts Payable	799	-
Total Current Liabilities	<u>799</u>	<u>-</u>
Net Assets		
Net Assets without Donor Restrictions	276,064	123,258
Net Assets - Board Restricted	-	64,935
Net Assets with Donor Restrictions	212,104	218,618
Total Net Assets	<u>488,168</u>	<u>406,811</u>
Total Liabilities and Net Assets	<u><u>\$ 488,967</u></u>	<u><u>\$ 406,811</u></u>

Cure VCP Disease, Inc.
Statements of Activities
For the Years Ended December 31, 2023 and 2022

	<u>2023</u>			<u>2022</u>		
	without Donor Restrictions	Net Assets with Donor Restrictions	Total	without Donor Restrictions	Net Assets with Donor Restrictions	Total
Revenues and Other Support						
Contribution Income	\$ 98,181	\$ 200,000	\$ 298,181	\$ 68,965	\$ 200,000	\$ 268,965
Fundraising Income, net	118,708	-	118,708	55,370	-	55,370
Program Income - Scientific Conference	14,596	-	14,596	1,691	-	1,691
Release from Restrictions	206,514	(206,514)	-	181,382	(181,382)	-
Total Revenues and Other Support	<u>437,999</u>	<u>(6,514)</u>	<u>431,485</u>	<u>307,408</u>	<u>18,618</u>	<u>326,026</u>
Expenses						
Program Expenses	276,764	-	276,764	215,516	-	215,516
General and Administrative Expenses	19,977	-	19,977	16,641	-	16,641
Fundraising Expenses	53,387	-	53,387	28,443	-	28,443
Total Expenses	<u>350,128</u>	<u>-</u>	<u>350,128</u>	<u>260,600</u>	<u>-</u>	<u>260,600</u>
Change in Net Assets	87,871	(6,514)	81,357	46,808	18,618	65,426
Net Assets, Beginning of Year	188,193	218,618	406,811	141,385	200,000	341,385
Net Assets, End of Year	<u>\$ 276,064</u>	<u>\$ 212,104</u>	<u>\$ 488,168</u>	<u>\$ 188,193</u>	<u>\$ 218,618</u>	<u>\$ 406,811</u>

The accompanying notes are an integral part of these financial statements

Cure VCP Disease, Inc.
Statement of Functional Expenses
For the Year Ended December 31, 2023

	Program	Management and General	Fundraising	Total
Compensation	\$ 71,226	\$ 1,210	\$ 36,331	\$ 108,767
Research Services	86,939	-	-	86,939
Grants	62,123	-	-	62,123
Conferences	29,870	150	-	30,020
Travel	20,726	-	1,224	21,950
Fundraising Expenses	-	-	13,750	13,750
Professional Fees	-	9,094	1,000	10,094
Technology	1,650	2,066	1,029	4,745
Office Expenses	377	2,760	-	3,137
Research Equipment	3,093	-	-	3,093
Insurance	-	2,760	-	2,760
Bank Service Charge	-	1,439	53	1,492
Miscellaneous	499	498	-	997
Educational Resources	261	-	-	261
Total Functional Expenses	\$ 276,764	\$ 19,977	\$ 53,387	\$ 350,128

The accompanying notes are an integral part of these financial statements.

Cure VCP Disease, Inc.
Statement of Functional Expenses
For the Year Ended December 31, 2022

	Program	Management and General	Fundraising	Total
Compensation	\$ 50,113	\$ -	\$ -	\$ 50,113
Research Services	38,703	1,500	-	40,203
Grants	52,592	-	-	52,592
Conferences	33,099	-	-	33,099
Travel	22,496	-	-	22,496
Fundraising Expenses	-	-	26,250	26,250
Professional Fees	-	5,398	-	5,398
Technology	2,106	1,763	2,193	6,062
Office Expenses	1,210	2,428	-	3,638
Research Equipment	2,218	-	-	2,218
Insurance	-	2,911	-	2,911
Bank Service Charge	-	2,641	-	2,641
Educational Resources	12,979	-	-	12,979
Total Functional Expenses	\$ 215,516	\$ 16,641	\$ 28,443	\$ 260,600

The accompanying notes are an integral part of these financial statements.